{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:59:33Z","timestamp":1776988773452,"version":"3.51.4"},"reference-count":73,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.hfc.2011.03.004","type":"journal-article","created":{"date-parts":[[2011,7,11]],"date-time":"2011-07-11T18:47:22Z","timestamp":1310410042000},"page":"299-311","source":"Crossref","is-referenced-by-count":8,"title":["Molecular Mechanisms of Hypertension and Heart Failure Due to Antiangiogenic Cancer Therapies"],"prefix":"10.1016","volume":"7","author":[{"given":"Meredith L.","family":"Rees","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarif Y.","family":"Khakoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.hfc.2011.03.004_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.133.2.275","article-title":"Isolation of a tumor factor responsible for angiogenesis","volume":"133","author":"Folkman","year":"1971","journal-title":"J\u00a0Exp Med"},{"issue":"32","key":"10.1016\/j.hfc.2011.03.004_bib2","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"9604","key":"10.1016\/j.hfc.2011.03.004_bib3","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hfc.2011.03.004_bib4","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/cncr.23460","article-title":"Heart failure associated with sunitinib malate","volume":"112","author":"Khakoo","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.hfc.2011.03.004_bib5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.cmet.2007.04.003","article-title":"Myocardial angiogenesis: its absence makes the growing heart founder","volume":"5","author":"Dorn","year":"2007","journal-title":"Cell Metab"},{"issue":"22","key":"10.1016\/j.hfc.2011.03.004_bib6","doi-asserted-by":"crossref","first-page":"9112","DOI":"10.1158\/0008-5472.CAN-08-0851","article-title":"Does the renin\u2013angiotensin system participate in regulation of human vasculogenesis and angiogenesis?","volume":"68","author":"Khakoo","year":"2008","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.hfc.2011.03.004_bib7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tcb.2008.01.006","article-title":"Mitochondria in cancer cells: what is so special about them?","volume":"18","author":"Gogvadze","year":"2008","journal-title":"Trends Cell Biol"},{"issue":"3","key":"10.1016\/j.hfc.2011.03.004_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A\u00a0small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.hfc.2011.03.004_bib9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.hfc.2011.03.004_bib11","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hfc.2011.03.004_bib12","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ajh.2010.25","article-title":"Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis","volume":"23","author":"Ranpura","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.hfc.2011.03.004_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005392.pub3","article-title":"Antiangiogenic therapies for metastatic colorectal cancer","volume":"3","author":"Wagner","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.hfc.2011.03.004_bib14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1634\/theoncologist.2009-0252","article-title":"Antivascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?","volume":"15","author":"Vaklavas","year":"2010","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.hfc.2011.03.004_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3816\/CBC.2010.n.016","article-title":"Integrating bevacizumab into the treatment of patients with early stage breast cancer: focus on cardiac safety","volume":"10","author":"Yardley","year":"2010","journal-title":"Clin Breast Cancer"},{"issue":"26","key":"10.1016\/j.hfc.2011.03.004_bib16","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2011.03.004_bib17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hfc.2011.03.004_bib18","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hfc.2011.03.004_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hfc.2011.03.004_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hfc.2011.03.004_bib21","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1200\/JCO.2005.02.0503","article-title":"Mechanisms of hypertension associated with BAY 43-9006","volume":"24","author":"Veronese","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hfc.2011.03.004_bib22","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hfc.2011.03.004_bib23","first-page":"512","article-title":"Sorafenib-induced acute myocardial infarction due to coronary artery spasm","volume":"54","author":"Arima","year":"2009","journal-title":"J\u00a0Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12012-009-9056-0","article-title":"Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib","volume":"10","author":"Hasinoff","year":"2010","journal-title":"Cardiovasc Toxicol"},{"issue":"5","key":"10.1016\/j.hfc.2011.03.004_bib25","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1177\/0192623310373775","article-title":"Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity","volume":"38","author":"French","year":"2010","journal-title":"Toxicol Pathol"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","article-title":"Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma","volume":"12","author":"Rock","year":"2007","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.hfc.2011.03.004_bib27","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1124\/mol.108.050104","article-title":"Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib","volume":"74","author":"Hasinoff","year":"2008","journal-title":"Mol Pharmacol"},{"issue":"9544","key":"10.1016\/j.hfc.2011.03.004_bib28","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hfc.2011.03.004_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol"},{"issue":"9","key":"10.1016\/j.hfc.2011.03.004_bib31","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","article-title":"Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis","volume":"20","author":"Di Lorenzo","year":"2009","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.hfc.2011.03.004_bib32","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdn168","article-title":"Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate","volume":"19","author":"Telli","year":"2008","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.hfc.2011.03.004_bib33","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","article-title":"Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer: a phase II study","volume":"8","author":"Rixe","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hfc.2011.03.004_bib34","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1345\/aph.1M251","article-title":"Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma","volume":"44","author":"LaPlant","year":"2010","journal-title":"Ann Pharmacother"},{"issue":"12","key":"10.1016\/j.hfc.2011.03.004_bib35","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.hfc.2011.03.004_bib36","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hfc.2011.03.004_bib37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.taap.2009.12.032","article-title":"The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity","volume":"244","author":"Hasinoff","year":"2010","journal-title":"Toxicol Appl Pharmacol"},{"issue":"5","key":"10.1016\/j.hfc.2011.03.004_bib38","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hfc.2011.03.004_bib39","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/cvr\/cvp270","article-title":"VEGF receptor switching in heart development and disease","volume":"84","author":"Madonna","year":"2009","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.hfc.2011.03.004_bib41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MNH.0b013e3283361c24","article-title":"Receptor and nonreceptor tyrosine kinases in vascular biology of hypertension","volume":"19","author":"Yogi","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev.med.48.1.489","article-title":"Nitric oxide synthase: role in the genesis of vascular disease","volume":"48","author":"Cooke","year":"1997","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.hfc.2011.03.004_bib43","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1152\/physrev.1999.79.4.1283","article-title":"Mechanism of action and in vivo role of platelet-derived growth factor","volume":"79","author":"Heldin","year":"1999","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1016\/j.hfc.2011.03.004_bib44","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00029330-200802010-00010","article-title":"Crosstalk between angiotensin II and platelet derived growth factor receptor BB mediated signal pathways in cardiomyocytes","volume":"121","author":"Wang","year":"2008","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.hfc.2011.03.004_bib45","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1242\/dev.126.14.3047","article-title":"Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse","volume":"126","author":"Hellstrom","year":"1999","journal-title":"Development"},{"issue":"2","key":"10.1016\/j.hfc.2011.03.004_bib46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1172\/JCI5028","article-title":"Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal","volume":"103","author":"Benjamin","year":"1999","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.hfc.2011.03.004_bib47","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1242\/dev.125.9.1591","article-title":"A\u00a0plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF","volume":"125","author":"Benjamin","year":"1998","journal-title":"Development"},{"issue":"4","key":"10.1016\/j.hfc.2011.03.004_bib48","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejheart.2006.10.007","article-title":"Intramyocardial injection of vascular endothelial growth factor gene improves cardiac performance and inhibits cardiomyocyte apoptosis","volume":"9","author":"Ruixing","year":"2007","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.hfc.2011.03.004_bib49","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1161\/01.RES.0000217342.83731.89","article-title":"Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs","volume":"98","author":"Ferrarini","year":"2006","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.hfc.2011.03.004_bib50","doi-asserted-by":"crossref","first-page":"H1393","DOI":"10.1152\/ajpheart.00871.2005","article-title":"Bioenergetic and functional consequences of stem cell-based VEGF delivery in pressure-overloaded swine hearts","volume":"290","author":"Wang","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"10.1016\/j.hfc.2011.03.004_bib51","doi-asserted-by":"crossref","first-page":"H389","DOI":"10.1152\/ajpheart.01393.2007","article-title":"Exercise-induced expression of VEGF and salvation of myocardium in the early stage of myocardial infarction","volume":"296","author":"Wu","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/cvr\/cvp178","article-title":"Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signaling pathway","volume":"84","author":"Zhou","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hfc.2011.03.004_bib53","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1073\/pnas.091415198","article-title":"A\u00a0cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function","volume":"98","author":"Giordano","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.hfc.2011.03.004_bib54","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1096\/fj.09-143180","article-title":"Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction","volume":"24","author":"Zentilin","year":"2010","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.hfc.2011.03.004_bib55","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1172\/JCI3058","article-title":"PDGF mediates cardiac microvascular communication","volume":"102","author":"Edelberg","year":"1998","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib56","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00019501-200402000-00009","article-title":"Platelet-derived growth factor improves cardiac function in a rodent myocardial infarction model","volume":"15","author":"Zheng","year":"2004","journal-title":"Coron Artery Dis"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1172\/JCI25878","article-title":"Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers","volume":"116","author":"Hsieh","year":"2006","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.hfc.2011.03.004_bib58","doi-asserted-by":"crossref","first-page":"e7325","DOI":"10.1371\/journal.pone.0007325","article-title":"Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model","volume":"4","author":"Das","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.hoc.2008.11.004","article-title":"Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors","volume":"23","author":"Chintalgattu","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"issue":"21","key":"10.1016\/j.hfc.2011.03.004_bib60","doi-asserted-by":"crossref","first-page":"15926","DOI":"10.1074\/jbc.M909616199","article-title":"Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor \u00ce2\u00a0receptor","volume":"275","author":"Heeneman","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.hfc.2011.03.004_bib61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/A:1026506801659","article-title":"Mechanical stretch augments PDGF receptor \u03b2 expression and protein tyrosine phosphorylation in pulmonary artery tissue and smooth muscle cells","volume":"215","author":"Tanabe","year":"2000","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.taap.2010.07.007","article-title":"Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells","volume":"248","author":"Zhao","year":"2010","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib63","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1752-8062.2008.00090.x","article-title":"Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase","volume":"2","author":"Kerkela","year":"2009","journal-title":"Clin Transl Sci"},{"issue":"4","key":"10.1016\/j.hfc.2011.03.004_bib64","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib65","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCRESAHA.109.206920","article-title":"Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics","volume":"106","author":"Cheng","year":"2010","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib66","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.205906","article-title":"The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy","volume":"106","author":"De Keulenaer","year":"2010","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.hfc.2011.03.004_bib67","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/CIRCRESAHA.109.210724","article-title":"Introduction to cardiotoxicity review series","volume":"106","author":"Force","year":"2010","journal-title":"Circ Res"},{"issue":"Suppl 15","key":"10.1016\/j.hfc.2011.03.004_bib68","doi-asserted-by":"crossref","first-page":"e15047","DOI":"10.1200\/jco.2010.28.15_suppl.e15047","article-title":"A\u00a0retrospective evaluation of antiangiogenic therapy induced hypertension in\u00a0metastatic renal cell carcinoma","volume":"28","author":"Wilhelm","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hfc.2011.03.004_bib69","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hfc.2011.03.004_bib70","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/annonc\/mdn729","article-title":"Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma","volume":"20","author":"Bono","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hfc.2011.03.004_bib71","unstructured":"Rini B, Cohen DP, Lu D, et\u00a0al. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Presented at: ASCO 2010 Genitourinary Cancers Symposium, San Francisco (CA), March 5\u20137, 2010."},{"issue":"8","key":"10.1016\/j.hfc.2011.03.004_bib72","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jacc.2007.04.074","article-title":"Polymorphisms of KDR gene are associated with coronary heart disease","volume":"50","author":"Wang","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"Suppl 15","key":"10.1016\/j.hfc.2011.03.004_bib73","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1200\/jco.2010.28.15_suppl.4601","article-title":"A\u00a0clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib","volume":"28","author":"Ilias-Khan","year":"2010","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713611000249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713611000249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T22:36:24Z","timestamp":1638052584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713611000249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S1551713611000249"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2011.03.004","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}